BPCIA Notification Provision Takes Center Stage in Two Federal Cases

By March 8, 2016 Generic Line No Comments

Notification requirements under the federal biosimilars law are getting renewed attention with two recent court filings: one, a petition to the U.S. Supreme Court, and the other an amicus brief before the U.S. Court of Appeals for the Federal Circuit.
Source: Generic Line